Studies revealed a positive effect of candesartan, a potent Angiotensin II type 1 receptor (AT1R) antagonist, on tumor growth, angiogenesis and metastasis in experimental mouse models suggesting that blockade of AT1R could be an effective anticancer strategy (1). This evidence concerns the gene AGTR1 and neoplasm.